Phase I trial evaluating the bioavailability, bioactivity and safety of two intranasal formulations of somatropin [CP 024] versus subcutaneously injected marketed human growth hormone in healthy volunteers
Latest Information Update: 21 Nov 2013
Price :
$35 *
At a glance
- Drugs Somatropin (Primary) ; Somatropin (Primary)
- Indications Somatotropin deficiency
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
- 21 Nov 2013 New trial record
- 06 Sep 2011 Interim data reported in a Critical Pharmaceuticals media release.